Chargement en cours...
(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor
Pazopanib is a recently approved, novel tyrosine kinase inhibitor specifically designed to impair angiogenesis by abrogating vascular endothelial growth factor receptor 2 (VEGFR-2) to exert its function. Pazopanib inhibits VEGF-induced endothelial cell proliferation in vitro and angiogenesis in vivo...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
AlphaMed Press
2010
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3227994/ https://ncbi.nlm.nih.gov/pubmed/20511320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2009-0274 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|